ObsEva is advancing a pipeline of orally administered, clinical-stage innovative compounds to treat women’s reproductive health conditions.
Month: June 2019
Ebopiprant
Oral PGF2α
receptor antagonist
Linzagolix – Endometriosis
(OBE2109)
Oral GnRH receptor antagonist
Linzagolix – Uterine Fibroids
(OBE2109)
Oral GnRH
receptor antagonist
Nolasiban (OBE001)
Oral oxytocin
receptor antagonist
Ebopiprant—Preterm Labor
Commercial Rights Exclusive Worldwide rights licensed to Organon Condition Preterm labor
Linzagolix – Endometriosis
Milestones EDELWEISS 3:Phase 3 Post-Rx F/U data expected (Q2:22)Phase 3 Post-Rx F/U-extension data expected (Q4:22) Clinical Studies Currently recruiting Commercial…
Linzagolix – Uterine Fibroids
Milestones EC & UK MHRA Marketing Authorization for Yselty® (linzagolix) in Q2:22 CHMP confirmation of positive opinion (Q2:22) NDA PDUFA…
Get in touch for partnering
Should you represent a pharmaceutical company seeking a strong and committed partner for the development and the commercialization of a…
At ObsEva, our growth strategy includes..
At ObsEva, our growth strategy includes the acquisition of additional novel clinical-stage assets that can address unmet needs for our…